Clinical Trials Logo

Clinical Trial Summary

This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of SHR-1210 + paclitaxel + cisplatin vs placebo+paclitaxel +cisplatin as 1L therapy for advanced esophageal cancer patients in China. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.


Clinical Trial Description

In this study, eligible subjects will be randomized into study arm or control arm. Treatment cycles of chemotherapy will be at most 6 cycles which would be decided by the investigators. Progression-free survival (PFS) assessed by the Independent Review Committee (IRC) and overall survival (OS) will be the primary outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03691090
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Contact
Status Completed
Phase Phase 3
Start date December 3, 2018
Completion date April 30, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03706326 - CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer Phase 1/Phase 2
Recruiting NCT05425472 - A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer Phase 2
Recruiting NCT05174156 - Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer Phase 2